Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3β

British Journal of Pharmacology

Volumn 147, Issue 5, 2006, Pages 575-582

  Whittle, Brendan J R ^a   Varga, Csaba ^b   Pósa, Anikó ^b   Molnár, Andor ^b   Collin, Marika ^a   Thiemermann, Christoph ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Glycogen synthase kinase 3 ; GSK 3 inhibitors; NF B; NF B p65; SB 415286; TDZD 8; TNBS colitis; TNF

Indexed keywords

2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOPEROXIDASE; PROTEIN SUBUNIT; SYNAPTOTAGMIN; THIADIAZOLIDINONE 8; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DOWN REGULATION; DRUG MEGADOSE; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; TISSUE INJURY; WEIGHT REDUCTION; WESTERN BLOTTING;

AMINOPHENOLS; ANIMALS; BODY WEIGHT; COLITIS; COLON; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; MALE; MALEIMIDES; ORGAN SIZE; PEROXIDASE; RATS; RATS, WISTAR; THIADIAZOLES; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644829249     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706509     Document Type: Article

References (44)

1. ALI, A., HOEFLICH, K.P. & WOODGETT, J.R. (2001). Glycogen synthase kinase-3: properties, functions, and regulation. Chem. Rev., 101, 2527-2540.
2. AMEHO, C.K., ADJEI, A.A., HARRISON, E.K., TAKESHITA, K., MORIOKA, T., ARAKAKI, Y., ITO, E., SUZUKI, I., KULKARNI, A.D., KAWAJIRI, A. & YAMAMOTO, S. (1997). Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut, 41, 487-493.
3. BARRY, F.A., GRAHAM, G.J., FRY, M.J. & GIBBINS, J.M. (2003). Regulation of glycogen synthase kinase 3 in human platelets: a possible role in platelet function? FEBS Lett., 553, 173-178.
4. BOBIN-DUBIGEON, C., COLLIN, X., GRIMAUD, N., ROBERT, J.M., LE BAUT, G. & PETIT, J.Y. (2001). Effects of tumour necrosis factor-alpha synthesis inhibitors on rat trinitrobenzene sulphonic acid-induced chronic colitis. Eur. J. Pharmacol., 431, 103-110.
5. BOUGHTON-SMITH, N.K., WALLACE, J.L., MORRIS, G.P. & WHITTLE, B.J.R. (1988a). The effect of anti-inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease in the rat. Br. J. Pharmacol., 94, 65-72.
6. BOUGHTON-SMITH, N.K., WALLACE, J.L. & WHITTLE, B.J.R. (1988b). Relationship between arachidonic acid metabolism, myeloperoxidase activity and leukocyte infiltration in a rat model of inflammatory bowel disease. Agents Actions, 25, 115-123.
7. BUSS, H., DORRIE, A., SCHMITZ, M.L., FRANK, R., LIVINGSTONE, M., RESCH, K. & KRACHT, M. (2004). Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J. Biol. Chem., 279, 49571-49574.
8. COGHLAN, M.P., CULBERT, A.A., CROSS, D.A., CORCORAN, S.L., YATES, J.W., PEARCE, N.J., RAUSCH, O.L., MURPHY, G.J., CARTER, P.S., ROXBEE, C.L., MILLS, D., BROWN, M.J., HAIGH, D., WARD, R.W., SMITH, D.G., MURRAY, K.J., REITH, A.D. & HOLDER, J.C. (2000). Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol., 7, 793-803.
9. CROSS, D.A., CULBERT, A.A., CHALMERS, K.A., FACCI, L., SKAPER, S.D. & REITH, A.D. (2001). Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem., 77, 94-102.
10. DEMARCHI, F., BERTOLI, C., SANDY, P. & SCHNEIDER, C. (2003). Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. J. Biol. Chem., 278, 39583-39590.
11. DESREUMAUX, P., DUBUQUOY, L., NUTTEN, S., PEUCHMAUR, M., ENGLARO, W., SCHOONJANS, K., DERIJARD, B., DESVERGNE, B., WAHLI, W., CHAMBON, P., LEIBOWITZ, M.D., COLOMBEL, J.F. & AUWERX, J. (2001). Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J. Exp. Med., 193, 827-838.
12. DUGO, L., COLLIN, M., ALLEN, D.A., PATEL, N.S., BAUER, I., MERVAALA, E.M., LOUHELAINEN, M., FOSTER, S.J., YAQOOB, M.M. & THIEMERMANN, C. (2005). GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit. Care Med., 33, 1903-1912.
13. FRAME, S. & COHEN, P. (2001). GSK3 takes centre stage more than 20 years after its discovery. Biochem. J., 359, 1-16.
14. GALVEZ, J., GARRIDO, M., MERLOS, M., TORRES, M.I. & ZARZUELO, A. (2000). Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat. Br. J. Pharmacol., 130, 1949-1959.
15. GROSS, E.R., HSU, A.K. & GROSS, G.J. (2004). Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ. Res., 94, 960-966.
16. HOEFLICH, K.P., LUO, J., RUBIE, E.A., TSAO, M.S., JIN, O. & WOODGETT, J.R. (2000). Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature, 406, 86-90.
17. HOLLENBACH, E., VIETH, M., ROESSNER, A., NEUMANN, M., MALFERTHEINER, P. & NAUMANN, M. (2005). Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J. Biol. Chem., 280, 14981-14988.
18. JIAN, Y.T., MAI, G.F., WANG, J.D., ZHANG, Y.L., LUO, R.C. & FANG, Y.X. (2005). Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J. Gastroenterol., 11, 1747-1752.
19. KARIN, M., YAMAMOTO, Y. & WANG, Q.M. (2004). The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov., 3, 17-26.
20. KISS, J., LAMARQUE, D., DELCHIER, J.C. & WHITTLE, B.J.R. (1997). Time-dependent actions of nitric oxide synthase inhibition on colonic inflammation induced by trinitrobenzene sulphonic acid in rats. Eur. J. Pharmacol., 336, 219-224.
21. KOHNO, H., SUZUKI, R., SUGIE, S. & TANAKA, T. (2005). Beta-catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sodium sulfate. Cancer Sci., 96, 69-76.
22. KRISTJANSSON, G., VENGE, P., WANDERS, A., LOOF, L. & HALLGREN, R. (2004). Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut, 53, 1806-1812.
23. LAWRANCE, I.C., WU, F., LEITE, A.Z., WILLIS, J., WEST, G.A., FIOCCHI, C. & CHAKRAVARTI, S. (2003). A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology, 125, 1750-1761.
24. MARTINEZ, A., ALONSO, M., CASTRO, A., PEREZ, C. & MORENO, F.J. (2002). First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem., 45, 1292-1299.
25. MEIJER, L., FLAJOLET, M. & GREENGARD, P. (2004). Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci., 25, 471-480.
26. MORRIS, G.P., BECK, P.L., HERRIDGE, M.S., DEPEW, W.T., SZEWCZUK, M.R. & WALLACE, J.L. (1989). Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology, 96, 795-803.
27. NEURATH, M., FUSS, I. & STROBER, W. (2000). TNBS-colitis. Int. Rev. Immunol., 19, 51-62.
28. RAAB, Y., GERDIN, B., AHLSTEDT, S. & HALLGREN, R. (1993). Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative colitis. Gut, 34, 1203-1206.
29. RIBBONS, K.A., THOMPSON, J.H., LIU, X., PENNLINE, K., CLARK, D.A. & MILLER, M.J. (1997). Anti-inflammatory properties of interleukin-10 administration in hapten-induced colitis. Eur. J. Pharmacol., 323, 245-254.
30. RUTGEERTS, P., VAN ASSCHE, G. & VERMEIRE, S. (2004). Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology, 126, 1593-1610.
31. SANCHEZ-HIDALGO, M., MARTIN, A.R., VILLEGAS, I. & ALARCON, D.L.L. (2005). Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem. Pharmacol., 69, 1733-1744.
32. SCHWABE, R.F. & BRENNER, D.A. (2002). Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol., 283, G204-G211.
33. SEGAIN, J.P., RAINGEARD, D.L.B., SAUZEAU, V., BOURREILLE, A., HILARET, G., CARIO-TOUMANIANTZ, C., PACAUD, P., GALMICHE, J.P. & LOIRAND, G. (2003). Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology, 124, 1180-1187.
34. STEINBRECHER, K.A., WILSON III, W., COGSWELL, P.C. & BALDWIN, A.S. (2005). Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription. Mol. Cell. Biol., 25, 8444-8455.
35. SUN, F.F., LAI, P.S., YUE, G., YIN, K., NAGELE, R.G., TONG, D.M., KRZESICKI, R.F., CHIN, J.E. & WONG, P.Y. (2001). Pattern of cytokine and adhesion molecule mRNA in hapten-induced relapsing colon inflammation in the rat. Inflammation, 25, 33-45.
36. SYKES, A.P., BHOGAL, R., BRAMPTON, C., CHANDER, C., WHELAN, C., PARSONS, M.E. & BIRD, J. (1999). The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment. Pharmacol. Ther., 13, 1535-1542.
37. TAKADA, Y., FANG, X., JAMALUDDIN, M.S., BOYD, D.D. & AGGARWAL, B.B. (2004). Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J. Biol. Chem., 279, 39541-39554.
38. TEN HOVE, T., CORBAZ, A., AMITAI, H., ALONI, S., BELZER, I., GRABER, P., DRILLENBURG, P., VAN DEVENTER, S.J., CHVATCHKO, Y. & TE VELDE, A.A. (2001). Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology, 121, 1372-1379.
39. UKIL, A., MAITY, S., KARMAKAR, S., DATTA, N., VEDASIROMONI, J.R. & DAS, P.K. (2003). Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br. J Pharmacol., 139, 209-218.
40. VILLEGAS, I., LA CASA, C., ORJALES, A. & ALARCON, D.L.L. (2003). Effects of dosmalfate, a new cytoprotective agent, on acute and chronic trinitrobenzene sulphonic acid-induced colitis in rats. Eur. J. Pharmacol., 460, 209-218.
41. WALLACE, J.L., MACNAUGHTON, W.K., MORRIS, G.P. & BECK, P.L. (1989). Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology, 96, 29-36.
42. WHITTLE, B.J.R., CAVICCHI, M. & LAMARQUE, D. (2003). Assessment of anticolitic drugs in the trinitrobenzene sulfonic acid (TNBS) rat model of inflammatory bowel disease. In Inflammation Protocols: Methods in Molecular Biology, ed. Winyard, P.G. & Willoughby, D.A. Totowa, NJ: Humana Press, pp 209-222.
43. WOODRUFF, T.M., ARUMUGAM, T.V., SHIELS, I.A., REID, R.C., FAIRLIE, D.P. & TAYLOR, S.M. (2003). A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J. Immunol., 171, 5514-5520.
44. YAMADA, Y., MARSHALL, S., SPECIAN, R.D. & GRISHAM, M.B. (1992). A comparative analysis of two models of colitis in rats. Gastroenterology, 102, 1524-1534.